Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May; 10(6):957-67.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials, Phase I as Topic
Combined Modality Therapy
Drug Evaluation, Preclinical
Humans
Neoplasms
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Pyrazoles
Pyrimidines
Treatment Outcome
authors with profiles
Jennifer Ruth Brown, Ph.D., M.D.
Matthew Steven Davids, M.D.